Adicet bio announces first patient dosed in phase 1 clinical trial of adi-001 in treatment-refractory rheumatoid arthritis (ra)

Redwood city, calif.--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today announced that the first patient has been dosed in its phase 1 clinical trial evaluating adi-001 in treatment-refractory ra. “dosing the first patient in our clinical study of adi-001 in treatment-refractory ra marks an important milestone in our phase 1 program, which is now en.
ACET Ratings Summary
ACET Quant Ranking